生物活性：Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface[1][2].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘代因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
然而，Ivacaftor (VX-770，HY-13017) 这种 CFTR 增效剂，有助于延长细胞表面 CFTR 蛋白通道的开放时间。Tezacaftor 与 Ivacaftor 结合，显示出对囊性纤维化和 CFTR Phe508del 突变纯合子疾病的有力效果。此外，Elexacaftor (VX-445，HY-111772) 也是一种 CFTR 校正器。 Elexacaftor-Tezacaftor-Ivacaftor 针对至少有一个 Phe508del 突变的囊性纤维化（CF），通常可避免肺移植适应症[3][4]。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Tezacaftor-d4 相关抗体:
Calumenin Antibody (YA813)
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT05599230CHC MontlegiaCystic FibrosisSeptember 1, 2022NCT02015507Vertex Pharmaceuticals IncorporatedCystic FibrosisJanuary 2014Phase 1NCT01531673Vertex Pharmaceuticals IncorporatedCystic FibrosisFebruary 2012Phase 2 NCT05576324University of Erlangen-Nürnberg Medical SchoolCystic FibrosisDecember 30, 2020NCT03029455Vertex Pharmaceuticals IncorporatedCystic FibrosisNovember 2016Phase 1NCT02070744Vertex Pharmaceuticals IncorporatedCystic FibrosisMarch 2014Phase 2NCT05699148Nottingham University Hospitals NHS TrustCystic FibrosisApril 1, 2022NCT02516410Vertex Pharmaceuticals IncorporatedCystic FibrosisAugust 2015Phase 3NCT02347657Vertex Pharmaceuticals IncorporatedCystic FibrosisJanuary 2015Phase 3
分子量：524.52
Formula：C26H23D4F3N2O6
CAS 号：1961280-24-9
非标记 CAS：1152311-62-0
性状：固体
颜色：White to off-white
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years
In solvent：-80°C：6 months，-20°C：1 month